First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy

dc.contributor.author	Isikdogan, A
dc.contributor.author	Turk, H
dc.contributor.author	Bilir, C
dc.contributor.author	Sendur, M
dc.contributor.author	Karabulut, B
dc.contributor.author	Artac, M
dc.contributor.author	Cicin, I
dc.contributor.author	Geredeli, C
dc.contributor.author	Alacacioglu, A
dc.contributor.author	Kefeli, U
dc.contributor.author	Harputluoglu, H
dc.contributor.author	Bozkurt, O
dc.contributor.author	Cubukcu, E
dc.contributor.author	Tural, D
dc.contributor.author	Sakin, A
dc.contributor.author	Cil, T
dc.contributor.author	Dane, F
dc.contributor.author	Cevik, D
dc.contributor.author	Arslan, C
dc.contributor.author	Karadurmus, N
dc.contributor.author	Gumus, M
dc.contributor.author	Yalcin, S
dc.date.accessioned	2023-01-02T08:53:08Z
dc.date.available	2023-01-02T08:53:08Z
dc.date.issued	2022
dc.identifier.uri	http://hdl.handle.net/11616/86956
dc.source	ANNALS OF ONCOLOGY
dc.title	First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy
dc.title	in patients with metastatic colorectal cancer: Onco-colon Turkey study
dc.title	subgroup analysis

Bu öğenin dosyaları:

Dosyalar	Boyut	Biçim	Göster
Bu öğe ile ilişkili dosya yok.